US.DGX · Quest Diagnostics

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.8,
      "details": {
        "atrPct": 1.9164450263922421,
        "turnoverUsdM": 308.689009,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.DGX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 235.0228,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2.5,
        "rsi_score": 0.5,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 3.8,
      "take_profit_price": 256.6095,
      "target_multiplier": 1.9,
      "technical_strength": 1.55,
      "take_profit_percent": 5
    },
    "positionPoints": 1.8,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.3044986762319581,
    "stopLossPercent": 3.8328900527844842,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 84.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 71.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 13
  },
  "market": {
    "ma20": 236.5615,
    "ma50": 219.305,
    "close": 244.39,
    "prevClose": 241.3,
    "avgVolume20": 864425,
    "volumeRatio": 1.46,
    "changePercent": 1.28
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 13,
    "details": {
      "ret_5d": 0.042619498405268574,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 13,
      "vcp_bonus": 0,
      "vol_ratio": 1.4379962999857692,
      "ret_points": 8,
      "vol_points": 4,
      "range_ratio": 1.0238523616949955,
      "volat_points": 0,
      "day_range_pct": 0.021563934694545542,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 84.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 66,
        "contribution": 3.3
      },
      {
        "raw": 16.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 82,
        "contribution": 16.4
      },
      {
        "raw": 10.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 68,
        "contribution": 10.2
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 76,
        "contribution": 7.6
      },
      {
        "raw": 21.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 72,
        "contribution": 21.6
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "謹慎買入",
    "result": 71.1,
    "details": [
      "基本面分析總分: 3.3/5分",
      "資金流分析總分: 16.4/20分",
      "市場環境分析總分: 10.2/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.6/10分",
      "技術信號分析總分: 21.6/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 3.3,
      "資金流": 16.4,
      "市場環境": 10.2,
      "情緒分析": 6,
      "技術信號": 21.6,
      "風險管理": 7.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "一般",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.4,
          "roePoints": 0.4,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 308.689009,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 4,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.DGX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.01
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 709.1885013500001,
                "ma50": 713.4416018399997,
                "name": "QQQ",
                "close": 713.44,
                "points": 1
              },
              "spy": {
                "ma20": 762.32700215,
                "ma50": 751.7496043999998,
                "name": "SPY",
                "close": 765.71997,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.9164450263922421,
          "atrPoints": 4,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141283760,
                "url": "https://finnhub.io/api/news?id=c30d5354e46ad88c54ed8c721c8bdc3fcb2949ea541ef2057d4c3ec993cc5c35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.",
                "category": "company",
                "datetime": 1787330580,
                "headline": "Is it the Right Time to Retain DGX Stock in Your Portfolio?"
              },
              {
                "id": 141283764,
                "url": "https://finnhub.io/api/news?id=b4fc9be2a5861ea980b8fcafad24bd1e28e83c7234cd7a90abacddcf2d4626b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1787321702,
                "headline": "Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?"
              },
              {
                "id": 141283761,
                "url": "https://finnhub.io/api/news?id=9b7af376234d46216302cd1b88a42b88d804fa085ac0af9da002e6be19e4f53e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...",
                "category": "company",
                "datetime": 1787209981,
                "headline": "Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal"
              },
              {
                "id": 141283766,
                "url": "https://finnhub.io/api/news?id=153a33d2b30a5f92b854b9cf7cbc805d6166ef3aa40451807b72088301a25ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...",
                "category": "company",
                "datetime": 1787188641,
                "headline": "Is Quest Diagnostics (DGX) Still Worth A Look After A 92% Run?"
              },
              {
                "id": 141283762,
                "url": "https://finnhub.io/api/news?id=dbf64f79f64fd58736b6a3e1dbf8ec71613e7a372c25d65fe8dc17f2fed7e0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
                "category": "company",
                "datetime": 1787072404,
                "headline": "Quest Diagnostics (DGX) Upgraded to Buy: Here's Why"
              },
              {
                "id": 141244640,
                "url": "https://finnhub.io/api/news?id=20953e31f24da77a3f33a10b4c7fbcd3a7381e5351819e80edfc211f24131541",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.",
                "category": "company",
                "datetime": 1787041268,
                "headline": "Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield"
              },
              {
                "id": 141283763,
                "url": "https://finnhub.io/api/news?id=3799321850299dfebd18e307c44194a4182bd06002047280bc17baaf4916e732",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1786726802,
                "headline": "Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know"
              },
              {
                "id": 141125945,
                "url": "https://finnhub.io/api/news?id=a47c1c2fabcc06df1f54dca14d236b7379eb743f9ec94460efcd119c506f2d6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) has drawn fresh attention after raising its full year 2026 revenue and earnings guidance, alongside reporting second quarter results that showed higher sales and net income versus the prior year. See our latest analysis for Quest Diagnostics. Quest Diagnostics shares have climbed strongly over 2026 so far, with a year to date share price return of 34.48% and a 90 day share price return of 23.58%. That momentum sits alongside a 1 year total shareholder return of 37.26%...",
                "category": "company",
                "datetime": 1785953458,
                "headline": "Is Quest Diagnostics (DGX) A Bargain Following Raised Guidance And Strong Quarterly Results?"
              }
            ],
            "raw_source": [
              {
                "id": 141283760,
                "url": "https://finnhub.io/api/news?id=c30d5354e46ad88c54ed8c721c8bdc3fcb2949ea541ef2057d4c3ec993cc5c35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.",
                "category": "company",
                "datetime": 1787330580,
                "headline": "Is it the Right Time to Retain DGX Stock in Your Portfolio?"
              },
              {
                "id": 141283764,
                "url": "https://finnhub.io/api/news?id=b4fc9be2a5861ea980b8fcafad24bd1e28e83c7234cd7a90abacddcf2d4626b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1787321702,
                "headline": "Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?"
              },
              {
                "id": 141275203,
                "url": "https://finnhub.io/api/news?id=089773ba910b7d77165aa048f75b768edf24f1414da740123cd9e15d62e665de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.",
                "category": "company",
                "datetime": 1787257290,
                "headline": "Hims & Hers Health Stock Trades Below The Market On Revenue And Above It On Cash"
              },
              {
                "id": 141283761,
                "url": "https://finnhub.io/api/news?id=9b7af376234d46216302cd1b88a42b88d804fa085ac0af9da002e6be19e4f53e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...",
                "category": "company",
                "datetime": 1787209981,
                "headline": "Quest Diagnostics (DGX) Could Be 30% Below Fair Value After Upgrade And WHOOP Deal"
              },
              {
                "id": 141283766,
                "url": "https://finnhub.io/api/news?id=153a33d2b30a5f92b854b9cf7cbc805d6166ef3aa40451807b72088301a25ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...",
                "category": "company",
                "datetime": 1787188641,
                "headline": "Is Quest Diagnostics (DGX) Still Worth A Look After A 92% Run?"
              },
              {
                "id": 141283762,
                "url": "https://finnhub.io/api/news?id=dbf64f79f64fd58736b6a3e1dbf8ec71613e7a372c25d65fe8dc17f2fed7e0c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
                "category": "company",
                "datetime": 1787072404,
                "headline": "Quest Diagnostics (DGX) Upgraded to Buy: Here's Why"
              },
              {
                "id": 141283776,
                "url": "https://finnhub.io/api/news?id=04b264d86ac1e07f5d8e919b4a93debd01928f472f7c923b1748772de3656742",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "BOSTON, August 18, 2026--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first time, making WHOOP Advanced Labs available without a membership. WHOOP Advanced Labs is powered in the U.S. by Quest Diagnostics (NYSE: DGX).",
                "category": "company",
                "datetime": 1787061600,
                "headline": "WHOOP Makes Advanced Labs Available Without a Wearable Membership"
              },
              {
                "id": 141244640,
                "url": "https://finnhub.io/api/news?id=20953e31f24da77a3f33a10b4c7fbcd3a7381e5351819e80edfc211f24131541",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) passes Best Dividend screen: dividend rating 7, profitability 7, health 6. Yield 1.46% with sustainable payout.",
                "category": "company",
                "datetime": 1787041268,
                "headline": "Quest Diagnostics (NYSE:DGX) Shows Dividend Quality Beyond the Headline Yield"
              },
              {
                "id": 141231125,
                "url": "https://finnhub.io/api/news?id=20166a2b2acd2263cfdbcc99fc419c59e514054bea615fc73fdbae8d84095aeb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445262091/image_1445262091.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.",
                "category": "company",
                "datetime": 1786867596,
                "headline": "IHF: Healthcare Dashboard For August"
              },
              {
                "id": 141283763,
                "url": "https://finnhub.io/api/news?id=3799321850299dfebd18e307c44194a4182bd06002047280bc17baaf4916e732",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1786726802,
                "headline": "Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know"
              },
              {
                "id": 141233184,
                "url": "https://finnhub.io/api/news?id=b2a121b5b85a7a5508e3d6aaa99f21902c8482bf25c1589fc2188a9960960350",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.",
                "category": "company",
                "datetime": 1786725000,
                "headline": "HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up"
              },
              {
                "id": 141206759,
                "url": "https://finnhub.io/api/news?id=c067faf0c1634ac60f102352c75ddfeda8c69f0af93964e9e913b74018d3c1e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "EYE beats Q2 earnings and revenue estimates, expands operating margin and raises its 2026 profit outlook despite gross margin pressure.",
                "category": "company",
                "datetime": 1786626180,
                "headline": "National Vision Stock Down Despite Q2 Earnings & Revenue Beat"
              },
              {
                "id": 141206752,
                "url": "https://finnhub.io/api/news?id=659ee02b225f8ed4a921b6c898a8d79914a526a79eab67069f99e681ffb2582e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.",
                "category": "company",
                "datetime": 1786626060,
                "headline": "TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises"
              },
              {
                "id": 141202450,
                "url": "https://finnhub.io/api/news?id=18bb8e50654636d5475babe63b4fb5fb1d1b65d919e63f3813f91c80c4740dbe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.",
                "category": "company",
                "datetime": 1786565700,
                "headline": "Quest Diagnostics Declares Quarterly Cash Dividend"
              },
              {
                "id": 141199695,
                "url": "https://finnhub.io/api/news?id=83b406a895b2ed6e006d593db9ba4a3e8ee2ebbb0837d4baec2ecbb05543e816",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.",
                "category": "company",
                "datetime": 1786468740,
                "headline": "Hims & Hers Stock Plunges Post Q2 Earnings Miss, Gross Margin Down"
              },
              {
                "id": 141202446,
                "url": "https://finnhub.io/api/news?id=bab940f55a7015d88f60068e2a5c3a85f4cdee542e259b301b823c86d91a00e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.",
                "category": "company",
                "datetime": 1786454220,
                "headline": "Alcon's Q2 Earnings and Revenues Surpass Estimates, Stock Climbs"
              },
              {
                "id": 141175551,
                "url": "https://finnhub.io/api/news?id=335ee49202be9ffff32971915dd2c0726283f0b283c39a280888d2ccb6cbefef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.",
                "category": "company",
                "datetime": 1786373040,
                "headline": "Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?"
              },
              {
                "id": 141175552,
                "url": "https://finnhub.io/api/news?id=eee9f1f73ba5090380f2701c2893296c2b81648f037f5e89f4a44803cadf2233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.",
                "category": "company",
                "datetime": 1786368120,
                "headline": "PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down"
              },
              {
                "id": 141149648,
                "url": "https://finnhub.io/api/news?id=23ea5ce12ca989bc8194b69e7daad6302e9ee390a675376aa73d23dc8c9d4466",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.",
                "category": "company",
                "datetime": 1786115820,
                "headline": "PBH Stock Up on Q1 Earnings and Revenue Beat, Fiscal '27 View Raised"
              },
              {
                "id": 141149640,
                "url": "https://finnhub.io/api/news?id=9330c5d081238104a84cc1a9ddf25b5c9eb1eb96172fe7a4c6eb81db3d1c6b84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.",
                "category": "company",
                "datetime": 1786115520,
                "headline": "RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y"
              },
              {
                "id": 141148177,
                "url": "https://finnhub.io/api/news?id=d125aba8d6bfc00d706132d273626c8dadaedc5c85eb89d47c934fce7ab53293",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.",
                "category": "company",
                "datetime": 1786113360,
                "headline": "Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation"
              },
              {
                "id": 141140760,
                "url": "https://finnhub.io/api/news?id=ee6d3d007ea52ed7ece2e1ffe250bd9d757cc332572d23d1547242731970e0d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.",
                "category": "company",
                "datetime": 1786038120,
                "headline": "BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down"
              },
              {
                "id": 141137448,
                "url": "https://finnhub.io/api/news?id=93ed2f326bd23efeabfa6448df1dc7e90b08fe15b5e30db3db486a67c99e3e92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.",
                "category": "company",
                "datetime": 1786028580,
                "headline": "STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading"
              },
              {
                "id": 141125945,
                "url": "https://finnhub.io/api/news?id=a47c1c2fabcc06df1f54dca14d236b7379eb743f9ec94460efcd119c506f2d6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) has drawn fresh attention after raising its full year 2026 revenue and earnings guidance, alongside reporting second quarter results that showed higher sales and net income versus the prior year. See our latest analysis for Quest Diagnostics. Quest Diagnostics shares have climbed strongly over 2026 so far, with a year to date share price return of 34.48% and a 90 day share price return of 23.58%. That momentum sits alongside a 1 year total shareholder return of 37.26%...",
                "category": "company",
                "datetime": 1785953458,
                "headline": "Is Quest Diagnostics (DGX) A Bargain Following Raised Guidance And Strong Quarterly Results?"
              },
              {
                "id": 141125946,
                "url": "https://finnhub.io/api/news?id=2f965def36b0f4573fda793bfc3ae5acff4f9e2ecca49602cee05d719f3fda89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DVA's second-quarter 2026 results show profit growth, but narrowing margins and a weaker commercial mix weigh on the performance.",
                "category": "company",
                "datetime": 1785953100,
                "headline": "DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down"
              },
              {
                "id": 141124452,
                "url": "https://finnhub.io/api/news?id=ea63b2e33a695cd49523d984a6b7ab8b6681be61e4c7280b6915c1c9cd3b04de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.",
                "category": "company",
                "datetime": 1785944820,
                "headline": "ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market"
              },
              {
                "id": 141124453,
                "url": "https://finnhub.io/api/news?id=1a7aca0e8c71ebda7f8740f1654c8f7408da5ed6d32912134eb3c869c199bc06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.",
                "category": "company",
                "datetime": 1785941640,
                "headline": "CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market"
              },
              {
                "id": 141122630,
                "url": "https://finnhub.io/api/news?id=f0d3f50c1dc72e766cb1b44a80ca4169797e7933306849ac32ca38bbb7329306",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.",
                "category": "company",
                "datetime": 1785939600,
                "headline": "CVS Health Q2 Earnings and Revenues Top Estimates, Stock Climbs"
              },
              {
                "id": 141122761,
                "url": "https://finnhub.io/api/news?id=a728e8db1e5fe4fdf2f8fc0040f4ed93ebb435cebe6d5b40f9a17ba7b5bffb48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics stock has climbed strongly over the past few years, yet current valuation checks suggest the shares may still trade below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach. Quest Diagnostics has returned 83.7% over the past 3 years, which means anyone who held through that period already saw a substantial gain and now needs to judge how much value is left in the current price. Recent strong demand for higher value diagnostic services can support...",
                "category": "company",
                "datetime": 1785939007,
                "headline": "Quest Diagnostics (DGX) Stock May Be 32% Undervalued As Guidance Rises"
              },
              {
                "id": 141111998,
                "url": "https://finnhub.io/api/news?id=83e1f9fb12f611558ef734564b6fd42e2870b2d019da6072c3946cd0eb8eb275",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.",
                "category": "company",
                "datetime": 1785858600,
                "headline": "IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market"
              },
              {
                "id": 141110312,
                "url": "https://finnhub.io/api/news?id=01e5837a924347cd1bedd5dda28d8136eee81b885372098288f763d19df0933a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.",
                "category": "company",
                "datetime": 1785850380,
                "headline": "HSIC Surpasses Q2 Earnings and Revenue Estimates, Stock Climbs"
              },
              {
                "id": 141125947,
                "url": "https://finnhub.io/api/news?id=b9dabf4508e5f3a470e64dce3b92989ea3b5c34c543c692b1ccc9d5b5f0d25cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "MIAMI, FL / ACCESS Newswire / August 4, 2026 / Digi Power X Inc. (NASDAQ:DGXX)(Cboe Canada:DGX) (the \"Company\" or \"Digi Power X\"), an AI data center infrastructure operator, plans to announce its financial results for the second quarter ended June ...",
                "category": "company",
                "datetime": 1785843000,
                "headline": "Digi Power X to Announce 2026 Q2 Financial Results and Provide Operations Update on August 14th"
              },
              {
                "id": 141101207,
                "url": "https://finnhub.io/api/news?id=ab4db3f301def98b9f07aa9343c6e7daf76ba96dee31f403cc70a8426f9e6464",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.",
                "category": "company",
                "datetime": 1785767820,
                "headline": "Quest Diagnostics Raises 2026 Outlook as Testing Demand Accelerates"
              },
              {
                "id": 141098941,
                "url": "https://finnhub.io/api/news?id=fa8690c87730d803e033e31089603829ffc0e49223082df0a95556e660c82a23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Credo Technology leads Zacks' latest market-beating highlights as strong stock gains and portfolio performance stand out despite a mixed U.S. economy.",
                "category": "company",
                "datetime": 1785760080,
                "headline": "Beat the Market the Zacks Way: Credo, Victoria's Secret, Bank of America in Focus"
              },
              {
                "id": 141079209,
                "url": "https://finnhub.io/api/news?id=a6471e0133a67e636ec4594009b47f90824127b7b349df3ce876842b2945e378",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.",
                "category": "company",
                "datetime": 1785506760,
                "headline": "Is DGX Stock Worth Buying After Its Strong 2026 Earnings Momentum?"
              },
              {
                "id": 141071591,
                "url": "https://finnhub.io/api/news?id=2836594e64296607bb7f6e294cf33070ec4c9783ecab2f8b748f782468ecb239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.",
                "category": "company",
                "datetime": 1785447512,
                "headline": "Is The Sharp Drop In Hims & Hers Health Stock A Reason To Buy?"
              },
              {
                "id": 141068616,
                "url": "https://finnhub.io/api/news?id=40b44f41e63b7857e9e36a8644fb6508a1c4e9f44f4936c01762e026d58a57b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.",
                "category": "company",
                "datetime": 1785429240,
                "headline": "Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026"
              },
              {
                "id": 141068617,
                "url": "https://finnhub.io/api/news?id=05552d6ffcc25a073722abed7f9de34a3d2ebb547fb64e72bc837087eb718b16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.",
                "category": "company",
                "datetime": 1785425340,
                "headline": "LH Stock Down Despite Q2 Earnings and Revenue Beat, Margins Rise"
              },
              {
                "id": 141064735,
                "url": "https://finnhub.io/api/news?id=e5d602d1fd4d3920503458497e710bf28773125c5d1bc8450c4fb986e395af12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Women who test positive for bacterial vaginosis (BV) were over three times more likely to also test positive for one or more non-viral sexually transmitted infections (STIs) than women who test negative for BV, according to a new Health Trends® study from Quest Diagnostics (NYSE: DGX) and Hologic, Inc.",
                "category": "company",
                "datetime": 1785411000,
                "headline": "Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics"
              },
              {
                "id": 141054323,
                "url": "https://finnhub.io/api/news?id=a3aef00cbe41993bf01f0396883fd69b084a50114577f7987ef97535873fe920",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.",
                "category": "company",
                "datetime": 1785330060,
                "headline": "Boston Scientific Q2 Earnings & Revenues Top Estimates, Stock Climbs"
              },
              {
                "id": 141048625,
                "url": "https://finnhub.io/api/news?id=c10d7a75055f2a583b8afc5f36faa890797ce268bd1e3e8f51fc1d73604febbe",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "JP Morgan  analyst Lisa Gill   maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.",
                "category": "company",
                "datetime": 1785232093,
                "headline": "JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250"
              },
              {
                "id": 141037264,
                "url": "https://finnhub.io/api/news?id=5e8c27d54f44ab00e93e1e4403a1e169894de3217aaf47d51b3a36d29c6f24e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "The company raised its outlook on booming AI demand, but the stock is telling a different story by standing still.",
                "category": "company",
                "datetime": 1785185769,
                "headline": "Equinix Stock Has A Message For Management"
              },
              {
                "id": 141093428,
                "url": "https://finnhub.io/api/news?id=2e72826e9fce214e985efc1a15a7724e829535bfb726bacc53f1ed0a566bda71",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 117 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up",
                "category": "company",
                "datetime": 1785158695,
                "headline": "Dell Upgraded, Tesla Downgraded: Updated Rankings on Top Blue-Chip Stocks"
              },
              {
                "id": 141029995,
                "url": "https://finnhub.io/api/news?id=cf95f748a926e675e4bca83137a81bef2476ef034cb3b876ef5e27d6384ad7b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Demand for medical testing services is rising.",
                "category": "company",
                "datetime": 1785118950,
                "headline": "Why Quest Diagnostics Stock Climbed This Past Week"
              },
              {
                "id": 141022424,
                "url": "https://finnhub.io/api/news?id=2a746b052ddb5d5a1b7207bb340cb81ee9971e6fd2b6cc8765fd924445859355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Earlier this week, Quest Diagnostics reported second-quarter 2026 results showing sales of US$3,043 million and diluted EPS of US$2.84, and raised its full‑year 2026 revenue guidance to US$11.95–US$12.05 billion and reported EPS to US$9.97–US$10.17. The company also continued its long-running capital return program, repurchasing 522,436 shares for US$100 million in the quarter, which supports earnings per share alongside higher‑value advanced diagnostics and growing test volumes. We’ll now...",
                "category": "company",
                "datetime": 1785039446,
                "headline": "Why Quest Diagnostics (DGX) Is Up 8.2% After Raising 2026 Guidance And Boosting Buybacks"
              },
              {
                "id": 141021084,
                "url": "https://finnhub.io/api/news?id=8b503bc07a82d85543b5b9c4f8159127ba37fbae2d480a66ee7fefc6770a3db1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics is back in focus after analysts lifted Fair Value estimates from US$223.44 to US$239.38, a move that has coincided with price targets shifting into the US$245 to US$265 range for more bullish views and into the low US$230s for more cautious ones. These adjustments reflect how analysts are weighing the Q2 beat, higher full year guidance, and ongoing volume and margin debates when refreshing their models. Read on to see what is driving this evolving narrative and how you can...",
                "category": "company",
                "datetime": 1785024976,
                "headline": "Quest Diagnostics (DGX) Stock Gets Fair Value Boost After Q2 Beat And Higher Guidance"
              },
              {
                "id": 140843515,
                "url": "https://finnhub.io/api/news?id=410c2274a53e42f425299ba3ba6dd240ae075acddeb862ae7f347dfd8789675e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Does CSX (CSX) have what it takes to be a top stock pick for momentum investors? Let's find out.",
                "category": "company",
                "datetime": 1784908803,
                "headline": "Are You Looking for a Top Momentum Pick? Why CSX (CSX) is a Great Choice"
              },
              {
                "id": 141019786,
                "url": "https://finnhub.io/api/news?id=608530e393c7a93c8dd6db84f3cbe8fcae8410e5fbef6d4402c71ff9a2a5f200",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Mizuho  analyst Ann Hynes   maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.",
                "category": "company",
                "datetime": 1784904099,
                "headline": "Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260"
              },
              {
                "id": 141019787,
                "url": "https://finnhub.io/api/news?id=41c0bd6b2f6001affdb1a796a27d3a2dc475918aea741a92403a50fb4c170034",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Truist Securities  analyst David Macdonald   maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.",
                "category": "company",
                "datetime": 1784902133,
                "headline": "Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250"
              },
              {
                "id": 141006631,
                "url": "https://finnhub.io/api/news?id=1c56ab7276b09cabb5ba57edf54c840ee29fe58faceb1690d18865a84cad7d25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
                "category": "company",
                "datetime": 1784898903,
                "headline": "Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?"
              },
              {
                "id": 141007264,
                "url": "https://finnhub.io/api/news?id=6259524bdc28aae7071c05f8528bf07868914612f2a7e90ed8bd98b3f7cbc92b",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Barclays  analyst Luke Sergott   maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.",
                "category": "company",
                "datetime": 1784891316,
                "headline": "Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250"
              },
              {
                "id": 141007265,
                "url": "https://finnhub.io/api/news?id=9f090ca50df5c43091ee39bcf08d10ddda08abef377de99955b9491dd800aca3",
                "image": "",
                "source": "Benzinga",
                "related": "DGX",
                "summary": "Baird  analyst Eric Coldwell   maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.",
                "category": "company",
                "datetime": 1784878397,
                "headline": "Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255"
              },
              {
                "id": 141003889,
                "url": "https://finnhub.io/api/news?id=fef3b5c95651e0fb5dce2ffb9e138695438f52f3324617220626e9d59ef41ef0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2271662218/image_2271662218.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "DGX",
                "summary": "Quest Diagnostics shows Q2 earnings beat, upgraded FY guidance, and continued market momentum. Check out why DGX stock is a buy.",
                "category": "company",
                "datetime": 1784872751,
                "headline": "Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results"
              },
              {
                "id": 141004530,
                "url": "https://finnhub.io/api/news?id=94fe730858e71cd13e2de869655feef15613c319b30ce2cac2656e8bcfd9c24b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "DGX",
                "summary": "Moby summary of Quest Diagnostics Incorporated's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1784853056,
                "headline": "Quest Diagnostics Incorporated Q2 2026 Earnings Call Summary"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 54,
            "discarded_article_count": 41
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 21.6,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 3,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 3,
            "vcp_reason": "波幅收縮(18.3%→5.5%)；量縮(v10/v30=0.75)；跌縮量(近10日4日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 4,
              "vol_ref": 995490,
              "down_days": 5,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 742640,
              "avg_vol_20": 878375,
              "avg_vol_30": 995490,
              "range_pct_10": 0.054830353124104926,
              "range_pct_20": 0.0910838823192439,
              "range_pct_30": 0.18282249682883916,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7460044802057278,
              "dist_to_20d_high": 0.005250692170738111,
              "down_shrink_days": 4,
              "breakout_level_20d": 245.67999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.29991031779550537
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.8,
            "details": {
              "atrPct": 1.9164450263922421,
              "turnoverUsdM": 308.689009,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.DGX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 235.0228,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2.5,
              "rsi_score": 0.5,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 3.8,
            "take_profit_price": 256.6095,
            "target_multiplier": 1.9,
            "technical_strength": 1.55,
            "take_profit_percent": 5
          },
          "positionPoints": 1.8,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.3044986762319581,
          "stopLossPercent": 3.8328900527844842,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 4.6836,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.92
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 179.46
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1865
    },
    "kdj": {
      "d": 69.05,
      "j": 87.74,
      "k": 75.28,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 75.44
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -1334400,
      "recentSlope": 110450,
      "previousSlope": -122260
    },
    "rsi": 78.14,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 224.0619,
      "position": "SAR喺價下",
      "distancePct": 8.32,
      "previousTrend": "上升"
    },
    "ma50": 219.305,
    "macd": {
      "macd": 6.2712858099002915,
      "trend": "中性偏多",
      "signal": 6.550260381728696,
      "histogram": -0.2789745718284049
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 236.3355,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 23
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.46,
      "score": 6,
      "avgVolume": 864425,
      "currentVolume": 1263100
    },
    "derived": {
      "ma20": 236.5615,
      "ma50": 219.305,
      "prevClose": 241.3,
      "avgVolume10": 811500,
      "avgVolume20": 864425,
      "changePercent": 1.28,
      "avgVolumeForScore": 864425
    },
    "ma_cross": {
      "ma20": 236.5615,
      "ma50": 219.305,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 235.735,
      "prevMa50": 218.4928,
      "spreadPct": 7.87,
      "isVolumeBreakout": true
    },
    "bollinger": {
      "lower": 230.2465,
      "upper": 242.8765,
      "position": "上半部"
    },
    "rsi_short": 83.27,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.46
    }
  }
}

{
  "close": 244.39,
  "volume": 1263100,
  "changePercent": 1.28
}